VANCOUVER, BC, May 12, 2015 (GLOBE NEWSWIRE) -- via PRWEB - According to a recently published report by iData Research (http://www.idataresearch.com), declines in the coronary stent market is due to decreases in ASP and unit sales in the last few years. However, the drug-eluting stent (DES) market has stabilized as new studies have confirmed the safety and efficacy of coronary stents when combined with a two-year course of anti-clotting medication. But despite this news, this segment continues to decline due to overall decreases in stenting procedures due to over-stenting and a preference for drug-based therapy in order to prevent heart attacks and death in patients with stable heart disease.
"Bare-metal and drug-eluting stents are both decreasing in price due to the increasing number of stent brands available, and the pricing pressures arising from increased competition," explains Dr. Kamran Zamanian, CEO of iData. "However, unit sales will slowly begin to recover as the problem of over-stenting will have been remedied through improved technology and education, and as reimbursement policies shift to include both inpatient and outpatient settings."
Other key findings from the 2015 iData Research report series entitled U.S. Market for Interventional Cardiology Devices:
Technological Advancements
Innovations in stent technology such as bioabsorbable stents, improved construction and thinner drug coatings will serve to increase their effectiveness, expand the number of stenting applications, and therefore drive the overall growth in the coronary stent market. Additionally, through the use of cardiovascular imaging techniques such as computerized tomography (CT), magnetic-resonance imaging (MRI), intravascular ultrasound (IVUS) and optical coherence tomography (OCT), more lesions that require stenting will be detected.
Leading Competitors
In 2014, Boston Scientific was the leading competitor in the coronary stent market due to the company's leading position in the DES market. They are currently competing with Abbott Laboratories' similar DES products. Both companies are attempting to use the lowering of prices and their well-established sales to promote their version of the device. Boston Scientific has released several new drug-eluting stents based on previous technology in an attempt to distance their DES portfolio from Abbott's technology.
Other notable competitors in the coronary stent market include Medtronic, Elixir Medical Corporation, Stentys, Biosensors, among others.
For Further Information
More on the coronary stent market in the U.S. can be found in the report published by iData entitled U.S. Market for Interventional Cardiology Devices. This report also covers the U.S. market segments for bare-metal and drug-eluting stents, PTCA and cutting balloons, balloon-inflation devices, interventional coronary catheters, interventional coronary guidewires, coronary embolic protection devices, coronary atherectomy devices, coronary thrombectomy devices, coronary chronic total occlusion crossers, introducer sheaths, coronary vascular closure devices, diagnostic coronary catheter and guidewires, intravascular ultrasound catheters, and optical coherence tomography catheters.
Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about coronary stent market data or procedure data, register online or email us at info(at)idataresearch(dot)net for a U.S. Market for Interventional Cardiology Devices report brochure and synopsis.
About Procedure Tracker
Additional procedure number data is available from iData's Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by country, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/05/prweb12715932.htm